UFP Technologies (UFPT) Q3 2026 earnings review
UFP Technologies keeps sales steady, but factory transfers lag behind
UFP Technologies, a contract manufacturer of medical devices and sterile packaging, kept sales steady after clearing a delayed order backlog while factory transfers lagged behind schedule. Sales from businesses owned a year ago rose 11%, above what the company's own second-half plan pointed to, and fast customer collections cut net debt by $33 million. Chief executive Mitch Rock said medical demand was broad, but by our math gross margin slipped slightly once last year's one-off labor costs are excluded.
| Sales from businesses owned a year ago | +11.1% 0% a year ago |
|---|---|
| Total revenue | $172.4M +11.6% from a year ago |
| Profit per share, excluding one-offs | $2.88 +20.5% from a year ago |
| Second-half underlying sales plan | Held implies ~4% Q4 growth at the middle |
⚖️ Verdict: 🟢 Bullish
The story got better because third-quarter sales held near $172 million without the backlog boost that helped the second quarter, and the first-half jump in unpaid customer bills reversed. One caution: beating the second-half sales plan says the plan was cautious, and the easy comparison against last year's factory disruption did much of the work while Dominican Republic factory transfers remain behind plan.
The question now is whether the 11% underlying growth rate is a lasting pace or the result of comparing against last year's unshipped orders. If demand is truly stronger, fourth-quarter growth will stay near double digits; if the easy comparison drove the beat, growth will slow toward the 4% rate implied by the second-half plan. The quarterly filing's customer table and fourth-quarter sales will settle it.
🐂 Bull Case
Sales Held Up After Backlog Cleared
Last quarter, UFP Technologies finished shipping a backlog of delayed orders at AJR, its safe-patient-handling business. Finance chief Ron Lataille had pointed to 6% to 9% growth in sales from businesses owned a year ago for the second half once that extra boost ended. Instead, third-quarter underlying sales rose 11.1%, and total revenue of $172.4 million stayed within 1% of the second quarter's $174.0 million.
Beating that second-half target says the company's plan was cautious, not that demand jumped. A year ago, labor turnover at AJR's Illinois factory left more than $8 million of orders unshipped. By our math, if last year's third quarter had included those missed shipments, underlying sales would have grown about 5.6% this quarter. Even so, keeping quarterly sales above $172 million shows orders did not drop after the backlog cleared.
What to watch: fourth-quarter underlying sales growth. By our math, the second-half target of 6% to 9% leaves just 1% to 7% growth for the fourth quarter, so another result near 10% would prove the higher sales pace is lasting.
Fast Collections Paid Down $21 Million of Debt
In the first half of the year, unpaid customer bills rose by $30.3 million and drained cash down to $9.0 million. That buildup raised concern that customers were taking longer to pay. In the third quarter, the medical-device manufacturer collected those bills and brought unpaid invoices down by $16.1 million to $97.2 million.
- Collection time: about 51 days of sales by our math, down from 59 days last quarter
- Total debt: $96.0 million, down $21.3 million in three months
- Net debt (debt minus cash): $75.4 million by our math, down $32.9 million from June
- Interest expense: $1.5 million, down 37.7% from a year ago
The faster collections turned profit into cash and cut interest costs, which helped profit per share grow faster than operating profit. Because collection time returned to last year's 51-day norm while quarterly sales stayed above $172 million, the first-half cash drain was a temporary timing blip rather than a problem with customer payments.
What to watch: cash flow from operations in the quarterly filing. A strong third-quarter cash figure will confirm that inventory and supplier payments matched the improvement in customer collections.
Medical Device Demand and Recent Deals Carry Growth
Chief executive Mitch Rock said year-to-date medical sales and sales to the top five medical customers both grew 11.7%, "reinforcing the balance, diversity, and durability of our portfolio". In the third quarter, medical-device revenue rose 12.5% to about $160.2 million by our math, while sales outside medical devices stayed nearly flat at $12.2 million.
Recent acquisitions are adding to that medical growth. Rock said the 2025 purchase of TPI, a maker of molded plastic parts in Puerto Rico, "has exceeded our expectations and provides an initial position in injection molding". The company also "invested in additional capacity at DAS Medical to support double-digit growth" in surgical equipment covers.
What to watch: the customer breakdown in the quarterly filing's footnotes. It will show whether the five largest accounts grew together or if one customer carried the group while robotic-surgery orders lagged.
🐻 Bear Case
Dominican Republic Transfers Remain Behind Plan
UFP Technologies has been moving safe-patient-handling production from the United States to lower-cost factories in the Dominican Republic. While Rock noted year-over-year progress at AJR, he admitted that "scheduled program transfers to the Dominican Republic and margin improvement remain behind plan". Last quarter, management said the third program transfer was waiting on customer approval.
Reported gross margin (the share of sales left after factory costs) rose 1.7 percentage points from a year ago to 29.4%, as cost of sales fell from 72.3% of revenue to 70.6%. That improvement is an illusion created by last year's disruption. In the third quarter of 2025, worker turnover at AJR added $3 million of extra labor costs; without that one-off cost, last year's gross margin was 29.6%. Against that clean baseline, gross margin actually slipped 0.2 percentage points by our math.
What to watch: commentary on the conference call about when the third AJR program will finish moving to Santiago. Until that transfer completes, running duplicate factory lines in the United States will hold back factory margins.
Bigger Acquisition Plans and Higher Overhead Test Discipline
Management views its growing deal pipeline and newly hired executives as strengths that will drive future growth. Rock said UFP is "working to expand our credit facility, increasing our capacity to invest in high-quality businesses" so it can "effectively onboard larger businesses". To prepare for bigger deals, the company added legal, operations and business-development leaders this year.
Those hires pushed selling and overhead expenses (SG&A) up 21.4% from a year ago to $23.2 million, or 13.4% of sales versus 12.3% last year. Excluding acquisition write-offs, overhead still rose 1.3 percentage points to 12.0% of sales, and share-based pay jumped 42.4% to $2.8 million. Buying larger companies also brings bigger integration risks after the 2024 AJR acquisition suffered a costly worker-eligibility problem.
What to watch: the size and borrowing terms of the expanded credit line once finalized. It will show how much debt management is willing to take on for its next acquisition.
Risks This Quarter Didn't Answer
Three standing risks from prior quarters received no new figures in the earnings release, because the detailed tables live in the quarterly filing or on the conference call.
- Largest robotics customer: sales to this account fell about 12% from a year ago in the second quarter; the quarterly filing's major-customer note will show if its share dropped below 21.0%.
- Raw material costs: management previously flagged higher petroleum-based plastic and foam costs tied to the conflict with Iran; the conference call will show whether price increases covered those costs.
- February 2026 cyber incident: the release repeated standard warnings about legal or regulatory fallout from the ransomware attack without giving a cost update.
💲 Other KPIs
Operating profit excluding one-offs rose 14.5% from a year ago to $30.1 million, or 17.5% of sales, up 0.4 percentage points. Profit per share excluding one-offs grew faster, up 20.5% to $2.88, because debt paydowns cut net interest expense by $0.9 million. Over the past four quarters, profit per share growth moved from a 4.0% drop to a 20.5% gain.
Stockpiles of raw materials and finished medical devices edged down $1.9 million from the second quarter after climbing $13.2 million in the first half. Compared with a year ago, inventories are up 13.9%, slightly ahead of the 11.6% rise in third-quarter sales as the manufacturer stocks new factory buildings in the Dominican Republic.
🔮 Guidance
Held. UFP Technologies does not publish numeric targets in its releases, and chief executive Mitch Rock said only that management is optimistic about 2027. On last quarter's call, the finance chief pointed to the 6% to 9% target range for second-half underlying sales. After 11.1% growth in the third quarter, that second-half range leaves 1% to 7% growth for the fourth quarter by our math (3.8% at the middle of the range).
❓ Key Questions
Did sales to the largest robotics customer fall again?
In the second quarter, revenue from UFP's historically largest robotic-surgery customer fell about 12% from a year ago to 21.0% of total sales. The third-quarter press release gave combined growth for the top five customers (11.7% year to date) without separating the two largest accounts.
When will the delayed Dominican Republic transfer finish?
Chief executive Mitch Rock said program transfers to the Dominican Republic and margin improvements at AJR remain behind plan. Investors need to know when the third safe-patient-handling program will pass customer inspection and how much duplicate U.S. factory costs weighed on third-quarter margins.
How large is the expanded credit line for acquisitions?
UFP is expanding its credit line to buy larger businesses after cutting net debt to $75.4 million. Management has not said how high it will take debt relative to profit or whether larger deals will dilute margins during integration.
What are the new robotic surgery programs contributing this year?
Last year, management said two new robotic-surgery programs would bring more than $10 million of sales in 2026, before shifting the timeline toward 2027 last quarter. The release did not give a third-quarter sales figure for robotic surgery.